Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antazoline + xylometazoline is a fixed-dose combination ophthalmic solution used for the symptomatic relief of allergic conjunctivitis. It contains antazoline, a small molecule H1 receptor antagonist, and xylometazoline, a small molecule sympathomimetic vasoconstrictor. Antazoline works by competitively blocking the binding of histamine to H1 receptors, thereby inhibiting histamine-mediated allergic responses such as itching, redness, and swelling. Xylometazoline acts as an agonist at alpha-adrenergic receptors, leading to vasoconstriction of the conjunctival blood vessels, which effectively reduces ocular congestion and edema. The product is marketed under brand names such as Otrivine-Antistin and is available both as a prescription medication and over-the-counter in various regions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antazoline + xylometazoline.